Hofseth Biocare ASA (HOFBF) has released an update.
Hofseth Biocare ASA’s subsidiary HBC Immunology has reported positive results from prostate cancer treatment studies using its leading peptide FT-002a in an oral formulation with standard hormonal therapy, showing enhanced anti-tumor activity and a reduction in biomarkers of free iron. The findings suggest FT-002a could improve the effectiveness of cancer treatments. The company aims to submit an Investigational New Drug (IND) application for its oral co-therapy in the fourth quarter of 2025.
For further insights into HOFBF stock, check out TipRanks’ Stock Analysis page.
